nach oben

Current Oncology Reports

Erschienen in:

01.04.2015 | Gastrointestinal Cancers (B Czito, Section Editor)

Adjuvant and Neoadjuvant Options in Resectable Gastric Cancer: Is There an Optimal Treatment Approach?

verfasst von: Xuguang Chen, Jennifer R. Eads, John B. Ammori, Aryavarta M. Kumar, Tithi Biswas, Jennifer A. Dorth

Erschienen in: Current Oncology Reports | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Gastric cancer is one of the most prevalent and deadliest forms of cancer worldwide. Even though neoadjuvant, perioperative, and adjuvant chemotherapy and/or radiation therapy may improve outcomes compared with surgery alone, the optimal combination of treatment modalities remains controversial. While European and North American trials established perioperative chemotherapy and adjuvant chemoradiation regimens for gastric cancer, Asian countries have focused on the use of adjuvant chemotherapy. This review summarizes results from contemporary randomized controlled trials and meta-analyses to elucidate the relative merits of each treatment approach.

de Martel C, Forman D, Plummer M. Gastric cancer: epidemiology and risk factors. Gastroenterol Clin N Am. 2013;42:219–40.CrossRef

Washington K. 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010;17:3077–9.CrossRefPubMed

Ajani JA, Bentrem DJ, Besh S, et al. Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Cancer Netw. 2013;11:531–46.

Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.CrossRefPubMed

Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22:2069–77.CrossRefPubMed

Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.CrossRefPubMed

Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.CrossRefPubMed

Raigani S, Hardacre JM, Kim J, Ammori JB. Trends in the surgical treatment of gastric adenocarcinoma. Ann Surg Oncol. 2014;21:569–74.CrossRefPubMedCentralPubMed

9.•

Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–21. The ACCORD 07 study demonstrated a benefit of perioperative chemotherapy on the rate of curative resection and five-year overall survival for gastric cancer.

10.•

Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Perioperative chemo (radio) therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev. 2013;5:Cd008107. This Cochrane Review from 2013 demonstrated that perioperative chemotherapy is associated with a 19 % relative increase in 5-year overall survival (HR 0.81, 95 % CI 0.73-0.89), which translates to an absolute increase of 9 % in survival.

11.••

Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315–21. The CLASSIC trial (Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer) randomized patients to gastrectomy with D2 LND with or without adjuvant XELOX chemotherapy.

12.

Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.CrossRefPubMed

13.••

Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30:2327–33. After 10 years of follow up, there was a benefit in overall survival associated with adjuvant CRT (HR 1.32, 95 % CI 1.10-1.60, p = 0.0046).

14.••

Lee J, Lim Do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268–73. The ARTIST trial found that there was no difference in disease-free survival between patients who received adjuvant chemotherapy versus chemoradiation. However, an unplanned subgroup analysis demonstrated that CRT improved relative disease-free survival by 32 % among 300 patients with positive lymph node involvement (HR 0.68, 95 % CI 0.47-0.99, p = 0.047).

15.

Hartgrink HH, van de Velde CJ, Putter H, et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol. 2004;30:643–9.CrossRefPubMed

16.

Schuhmacher C, Gretschel S, Lordick F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954. J Clin Oncol. 2010;28:5210–8.CrossRefPubMedCentralPubMed

17.

Li W, Qin J, Sun YH, Liu TS. Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol. 2010;16:5621–8.CrossRefPubMedCentralPubMed

18.

Liao Y, Yang ZL, Peng JS, et al. Neoadjuvant chemotherapy for gastric cancer: a meta-analysis of randomized, controlled trials. J Gastroenterol Hepatol. 2013;28:777–82.CrossRefPubMed

19.

Fujitani K. Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East. Dig Surg. 2013;30:119–29.CrossRefPubMed

20.

Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine and oxaliplatin (XELOX) for gastric cancer after D2 gastrectomy: final results from the CLASSIC trial. Ann Oncol. 2013;24:iv14.CrossRef

21.

Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.CrossRefPubMed

22.

Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011; 14: 113–123.

23.

Lee JH, Kim JG, Jung HK, et al. Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer. 2014;14:87–104.CrossRefPubMedCentralPubMed

24.

Tsuburaya A, Yoshida K, Kobayashi M, et al. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol. 2014;15:886–93.CrossRefPubMed

25.

Kang YK, Chang HM, Yook JH, et al. Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201). Br J Cancer. 2013;108:1245–51.CrossRefPubMedCentralPubMed

26.

Bajetta E, Floriani I, Di Bartolomeo M, et al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Ann Oncol. 2014;25:1373–8.CrossRefPubMed

27.

Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729–37.CrossRefPubMed

28.

Diaz-Nieto R, Orti-Rodriguez R, Winslet M. Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. Cochrane Database Syst Rev. 2013;9:CD008415.PubMed

29.

Markar SR, Karthikesalingam A, Jackson D, Hanna GB. Long-term survival after gastrectomy for cancer in randomized, controlled oncological trials: comparison between West and East. Ann Surg Oncol. 2013;20:2328–38.CrossRefPubMed

30.

Biffi R, Fazio N, Luca F, et al. Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World J Gastroenterol. 2010;16:868–74.PubMedCentralPubMed

31.

Menges M, Schmidt C, Lindemann W, et al. Low toxic neoadjuvant cisplatin, 5-fluorouracil and folinic acid in locally advanced gastric cancer yields high R-0 resection rate. J Cancer Res Clin Oncol. 2003;129:423–9.CrossRefPubMed

32.

Newman E, Marcus SG, Potmesil M, et al. Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer. J Gastrointest Surg. 2002;6:212–23. discussion 223.CrossRefPubMed

33.

Tepper JE, Gunderson LL. Radiation treatment parameters in the adjuvant postoperative therapy of gastric cancer. Semin Radiat Oncol. 2002;12:187–95.CrossRefPubMed

34.•

Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1982;8:1–11. The best characterization of patterns of failure after surgery alone comes from the University of Minnesota, where 109 gastric cancer patients underwent planned re-operations as part of a therapeutic regimen.

35.

Enzinger PC, Benedetti JK, Meyerhardt JA, et al. Impact of hospital volume on recurrence and survival after surgery for gastric cancer. Ann Surg. 2007;245:426–34.CrossRefPubMedCentralPubMed

36.

Coburn NG, Swallow CJ, Kiss A, Law C. Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer. 2006;107:2143–51.CrossRefPubMed

37.•

Ohri N, Garg MK, Aparo S, et al. Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis. Int J Radiat Oncol Biol Phys. 2013;86:330–5. This meta-analysis compares adjuvant chemotherapy to CRT and demonstrates an improvement in local-regional control and disease-free survival, but not overall survival, associated with CRT.

38.•

Shridhar R, Dombi GW, Weber J, et al. Adjuvant radiation therapy increases overall survival in node-positive gastric cancer patients with aggressive surgical resection and lymph node dissection: a SEER database analysis. Am J Clin Oncol. 2012;35:216–21. A SEER analysis of 11,630 gastric cancer patients who underwent surgery between 1990-2003 found that RT improved survival in all patients with positive lymph nodes, with a 5-year overall survival of 30 % with adjuvant RT versus 21 % without RT (p<0.0001).

39.

Fuchs CS, Tepper JE, Niedzwiecki D et al. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol. 2011; 29.

40.

Ajani JA, Mansfield PF, Janjan N, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22:2774–80.CrossRefPubMed

41.

Ajani JA, Winter K, Okawara GS, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24:3953–8.CrossRefPubMed

42.

Kim TH, Park SR, Ryu KW, et al. Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection. Int J Radiat Oncol Biol Phys. 2012;84:e585–92.CrossRefPubMed

43.

Kwon HC, Kim MC, Kim KH, et al. Adjuvant chemoradiation versus chemotherapy in completely resected advanced gastric cancer with D2 nodal dissection. Asia Pac J Clin Oncol. 2010;6:278–85.CrossRefPubMed

44.

Zhu WG, Xua DF, Pu J, et al. A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection. Radiother Oncol. 2012;104:361–6.CrossRefPubMed

45.

Huang YY, Yang Q, Zhou SW, et al. Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 lymphadenectomy: a meta-analysis. PLoS ONE. 2013;8:e68939.CrossRefPubMedCentralPubMed

46.

Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.CrossRefPubMed

Titel: Adjuvant and Neoadjuvant Options in Resectable Gastric Cancer: Is There an Optimal Treatment Approach?
verfasst von: Xuguang Chen
Jennifer R. Eads
John B. Ammori
Aryavarta M. Kumar
Tithi Biswas
Jennifer A. Dorth
Publikationsdatum: 01.04.2015
Verlag: Springer US
Erschienen in: Current Oncology Reports / Ausgabe 4/2015
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-015-0442-4

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Adjuvant and Neoadjuvant Options in Resectable Gastric Cancer: Is There an Optimal Treatment Approach?

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

Radical Surgery in Ovarian Cancer

Contemporary Surgical Options for Metastatic Colorectal Cancer

Adenocarcinoma of the Cervix: Should We Treat It Differently?

Precision Medicine in Breast Cancer: Genes, Genomes, and the Future of Genomically Driven Treatments

Activin Receptor Inhibitors—Dalantercept

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie